UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial of HP Acthar gel to manage exacerbations in relapsing and remitting multiple sclerosis (RRMS) patients.

HP Acthar gel is a US Food and Drug Administration (FDA) approved injectable repository corticotrophin.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The pilot, multi-centre, randomised, double-blind, placebo-controlled parallel group Phase IV trial is designed to evaluate HP Acthar gel’s safety and efficacy in patients with MS relapses of moderate severity and symptoms.

The trial will only include patients whose symptoms have not improved after treatment with an intravenous (IV) or oral high-dose corticosteroids, due to which the enrolment is expected to take several years for completion.

"Mallinckrodt is committed to providing alternative treatment options to patients who need them."

Mallinckrodt chief scientific officer and executive vice-president Steven Romano said: "Mallinckrodt is committed to providing alternative treatment options to patients who need them.

"Clinical experience and current labeling support the use of Acthar to speed recovery from relapses in MS. We are pleased to enrol the first patient in the OPTIONS trial to better understand the patients who will benefit from Acthar therapy, and to support its role in the management of RRMS."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial will assess the improvement in relapse symptoms using measures such as the expanded disability status scale (EDSS), MS impact scale (MSIS-29) and clinical global impressions-improvement scale (CGI-I).

The FDA approved the gel for the treatment of 19 indications, including dieresis, remission of proteinuria in nephrotic syndrome, exacerbations in systemic lupus erythematosus and systemic dermatomyositis.